InsidersTradesSigma
泽璟制药 Stock: price and management transactions · China · SSE / SZSE (CSRC)
Follow the 泽璟制药 stock price and the full management transaction log of the company, a listed equity based in China. Shares are quoted on CN CN, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 泽璟制药 has published 32 reports. Market capitalisation: €23.9bn. The latest transaction was reported on 16 April 2026 (Sale). Among the most active insiders: ZELIN SHENG(盛泽林). The full history is free.
32
Insider Decl.
0
Thresholds
·
31 ops.
Buy Volume
€3m
1 ops.
Sell Volume
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 14,106 of 25,791 companies
49.3
score / 100
Value32
Quality66
FCF yld-0.6%
Earn yld-0.5%
EV/EBITDA·
ROE34%
Gross mgn90%
Net mgn-20%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 16 April 2026
Declarations32 total
273,907 sharesA股XSHGSSE:273000000422970880
1,784 sharesA股XSHGSSE:173000005692962100
Ideal exit: 14 Apr 2023 (T+270)
200 sharesA股XSHGSSE:173000005662820540
Ideal exit: 3 Apr 2023 (T+270)
2,079 sharesA股XSHGSSE:173000005659772930
Ideal exit: 2 Apr 2023 (T+270)
1,050 sharesA股XSHGSSE:173000005649137920
Ideal exit: 28 Mar 2023 (T+270)
2,360 sharesA股XSHGSSE:173000005649150940
Ideal exit: 28 Mar 2023 (T+270)
2,000 sharesA股XSHGSSE:173000005547914300
Ideal exit: 18 Feb 2023 (T+270)
920 sharesA股XSHGSSE:173000005547914780
Ideal exit: 18 Feb 2023 (T+270)
8,000 sharesA股XSHGSSE:173000005547913570
Ideal exit: 18 Feb 2023 (T+270)
3,500 sharesA股XSHGSSE:173000005539713440
Ideal exit: 13 Feb 2023 (T+270)
27,380 sharesA股XSHGSSE:173000005378757300
Ideal exit: 17 Dec 2022 (T+270)
2,000 sharesA股XSHGSSE:173000005367543580
Ideal exit: 11 Dec 2022 (T+270)
30,000 sharesA股XSHGSSE:173000005367546620
Ideal exit: 11 Dec 2022 (T+270)
11,000 sharesA股XSHGSSE:173000005365277760
Ideal exit: 10 Dec 2022 (T+270)
8,820 sharesA股XSHGSSE:173000005365279170
Ideal exit: 10 Dec 2022 (T+270)
7,000 sharesA股XSHGSSE:173000005361184800
Ideal exit: 9 Dec 2022 (T+270)
25 of 32 declarations
About 泽璟制药
Zai Lab is a company focused on developing innovative medicines, particularly in oncology. It is listed on the Shanghai Stock Exchange.